[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

U.S. Market for Drug-Eluting and Bare Metal Stents 2009

May 2009 | 65 pages | ID: U96DBB8AB7AEN
iData Research Inc.

US$ 4,495.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In 2008, the U.S. market for drug eluting stents was valued at $1.95 billion, representing an increase of 1.6% over 2007. Overall average selling prices are predicted to decrease over the forecast period. Additional products included in this report: Bioabsorbable Stents, Bifurcated Stentsand bare-metal stents.
LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

1.1 MARKET FOR INTERVENTIONAL CARDIOLOGY DEVICES
1.2 BARE-METAL AND DRUG-ELUTING STENTS
1.3 PTCA AND CUTTING BALLOONS
1.4 BALLOON-INFLATION SYRINGES AND ANGIOPLASTY KITS
1.5 INTERVENTIONAL CATHETERS
1.6 INTERVENTIONAL GUIDEWIRES
1.7 EMBOLIC PROTECTION DEVICES
1.8 ATHERECTOMY DEVICES
1.9 THROMBECTOMY DEVICES
1.10 CHRONIC TOTAL OCCLUSION CROSSERS
1.11 INTRODUCER SHEATHS
1.12 VASCULAR CLOSURE DEVICES
1.13 DIAGNOSTIC CORONARY CATHETERS AND GUIDEWIRES
1.14 FRACTIONAL FLOW RESERVE GUIDEWIRES
1.15 IVUS CATHETERS
1.16 OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES
1.17 VULNERABLE PLAQUE DEVICES
1.18 PFO, ASD AND VSD DEVICES
1.19 PERCUTANEOUS MITRAL VALVE REPAIR DEVICES
1.20 AORTIC HEART VALVE REPLACEMENT DEVICES
1.21 LEADING COMPETITORS

RESEARCH METHODOLOGY

2.1 RESEARCH SCOPE
2.2 IDATA’S 9-STEP METHODOLOGY
  2.2.1 Step 1: Project Initiation & Team Selection
  2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research
  2.2.3 Step 3: Preparation for Interviews & Questionnaire Design
  2.2.4 Step 4: Performing Primary Research
  2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates
  2.2.6 Step 6: Market Forecast and Analysis
  2.2.7 Step 7: Identify Strategic Opportunities
  2.2.8 Step 8: Final Review and Market Release
  2.2.9 Step 9: Customer Feedback and Market Monitoring

BARE-METAL AND DRUG-ELUTING STENTS

3.1 INTRODUCTION
3.2 POPULATION AT RISK
3.3 PROCEDURE NUMBERS
3.4 MARKET ANALYSIS & FORECAST
  3.4.1 Units Sold by Type
  3.4.2 Bare-Metal Stent Market
    3.4.2.1 Bare-Metal Stent Market Drivers
    3.4.2.2 Bare-Metal Stent Market Limiters
  3.4.3 Drug-Eluting Stent Market
    3.4.3.1 Drug-Eluting Stent Market Drivers
    3.4.3.2 Drug-Eluting Stent Market Limiters
  3.4.4 Stents in Development
    3.4.4.1 Bioabsorbable Stents
    3.4.4.2 Bifurcated Stents.50
3.5 STENT MARKET BY DELIVERY PLATFORM
3.6 STENT MARKET BY SIZE
3.7 COMPETITIVE ANALYSIS
  3.7.1 Bare-Metal Stents
  3.7.2 Drug-Eluting Stents
  3.7.3 Potential New Market Participants

LIST OF FIGURES

EXECUTIVE SUMMARY
RESEARCH METHODOLOGY
BARE-METAL AND DRUG-ELUTING STENTS
Figure 4-1: Population at Risk, Market for Interventional Cardiology, U.S., 2005 – 2015
Figure 4-2: Angiography and Angioplasty Procedures, U.S., 2005 – 2015
Figure 4-3: Market for Coronary Stents by Type, U.S., 2005 – 2015
Figure 4-4: Units Sold, Market for Coronary Stents, U.S., 2005 – 2015
Figure 4-5: Coronary Stent Units by Type, U.S., 2005 – 2015
Figure 4-6: Market for Bare-Metal Stents, U.S., 2005 – 2015
Figure 4-7: Market Drivers and Limiters, Market for Bare-Metal Stents, U.S., 2008
Figure 4-8: Market for Drug-Eluting Stents, U.S., 2005 – 2015
Figure 4-9: Market Drivers and Limiters, Market for Drug-Eluting Stents, U.S., 2008
Figure 4-10: Coronary Stent Platforms in Development Not Approved by the FDA, 2008
Figure 4-11: Potential Market for Bioabsorbable Stents, U.S., 2013 – 2015
Figure 4-12: Potential Market for Bifurcated Stents, U.S., 2010 – 2015
Figure 4-13: Market for Coronary Stents by Delivery Platform, Units Sold, U.S., 2005 – 2015
Figure 4-14: Market for Coronary Stents by Size, U.S., 2008
Figure 4-15: Leading Competitors, Market for Bare-Metal Stents, U.S., 2008
Figure 4-16: Leading Competitors, U.S Market for Drug-Eluting Stents, 2008

LIST OF CHARTS

EXECUTIVE SUMMARY
Chart 1-1: Market for Interventional Cardiology Devices, U.S., 2008
Chart 1-2: Market for Coronary Stents, U.S., 2005 – 2015
Chart 1-3: Coronary Atherectomy Devices Market, U.S., 2005 – 2015
Chart 1-4: Coronary CTO Crosser Market, U.S., 2005 – 2015
Chart 1-5: Coronary Vascular Closure Devices, U.S., 2005 – 2015
Chart 1-6: Market for Diagnostic Coronary Catheters and Guidewires, U.S., 2005 – 2015
Chart 1-7: Penetration Rate of FFR Guidewires in PCI Procedures, U.S., 2005 - 2015
Chart 1-8: Number of IVUS Catheter Units Sold, U.S., 2005 – 2015
Chart 1-9: Optical Coherence Tomography Catheter Market, U.S., 2010 – 2015
Chart 1-10: Leading Competitors, Market for Interventional Cardiology, U.S., 2008
RESEARCH METHODOLOGY
BARE-METAL AND DRUG-ELUTING STENTS
Chart 4-1: Population at Risk, Market for Interventional Cardiology, U.S., 2005 – 2015
Chart 4-2: Age Group Most Likely to Undergo Cardiac Intervention: 60 to 69 Years Old, U.S., 2005 – 2015
Chart 4-3: Angioplasty and Angiography Procedures, U.S., 2005 – 2015
Chart 4-4: Market for Coronary Stents by Type, U.S., 2005 – 2015
Chart 4-5: Coronary Stent Units by Type, U.S., 2005 – 2015
Chart 4-6: Market for Bare-Metal Stents, U.S., 2005 – 2015
Chart 4-7: Market for Drug-Eluting Stents, U.S., 2005 – 2015
Chart 4-8: Penetration Rate for Bioabsorbable Stents, U.S., 2013 – 2015
Chart 4-9: Penetration Rate for Bifurcated Stents, U.S., 2010 – 2015
Chart 4-10: Market for Coronary Stents by Delivery Platform, Units Sold, U.S., 2005 – 2015
Chart 4-11: Market for Coronary Stents by Size, U.S., 2008
Chart 4-12: Leading Competitors, Market for Bare-Metal Stents, U.S., 2008
Chart 4-13: Leading Competitors, Market for Drug-Eluting Stents, U.S., 2008


More Publications